Share on LinkedInShare on LinkedIn

ARTICLE · 11 AUGUST 2022

Public Disclosure vs. Confidentiality Protection: The FCA Finds The Proper Balance

In FibroGen, Inc v Akebia Therapeutics, Inc, the Federal Court of Appeal set aside an order requiring a party to make certain fact witness statements from a discontinued action public,...

CanadaIntellectual Property

In FibroGen, Inc v Akebia Therapeutics, Inc, the Federal Court of Appeal set aside an order requiring a party to make certain fact witness statements from a discontinued action public, restoring the proper balance and safeguarding the confidentiality of documents that had been designated as confidential or highly confidential information.

Background

Akebia Therapeutics, Inc. and Otsuka Canada Pharmaceutical Inc. ("Akebia") brought an action to impeach several Canadian patents owned by FibroGen, Inc. ("FibroGen") in Federal Court File No. T-1004-18. The parties were engaged in related patent disputes in other jurisdictions, including the United States.

Certain procedural facts set the backdrop for this appeal.

We operate a free-to-view policy, asking only that you register in order to read all of our content. Please login or register to view the rest of this article.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

See more popular content from